
Cardiovascular Systems CSII
Quarterly report 2022-Q4
added 02-09-2023
Cardiovascular Systems General and Administrative Expenses 2011-2026 | CSII
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 171 M | 167 M | 170 M | - | - | - | - | - | - | - | 66.4 M | 62.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 171 M | 62.4 M | 127 M |
Quarterly General and Administrative Expenses Cardiovascular Systems
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 41.6 M | 44.5 M | 86.1 M | 41.7 M | 40.4 M | 41.9 M | 82.3 M | 41.4 M | 40.1 M | 40.3 M | 40.1 M | 41.4 M | 46.9 M | 46.8 M | 46.9 M | 46.8 M | 41.1 M | 41.2 M | 41.1 M | 41.2 M | 37 M | 35.9 M | 37 M | 35.9 M | 34 M | 36.9 M | 34 M | 36.9 M | 41.3 M | 41.4 M | 41.3 M | 41.4 M | 32.6 M | 33.5 M | 32.6 M | 33.5 M | 27.5 M | 25.4 M | 27.5 M | 25.4 M | 20.4 M | 20 M | 20.4 M | 20 M | 15.7 M | 15.4 M | 15.7 M | 15.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 86.1 M | 15.4 M | 36.8 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aziyo Biologics
AZYO
|
14.1 M | - | 1.37 % | $ 20.5 M | ||
|
Bruker Corporation
BRKR
|
894 M | $ 38.77 | -1.27 % | $ 5.78 K | ||
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
Acutus Medical
AFIB
|
14.1 M | - | -26.83 % | $ 2.62 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
Cognyte Software Ltd.
CGNT
|
163 M | $ 8.09 | 3.45 % | $ 581 M | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
Second Sight Medical Products
EYES
|
806 K | - | -0.97 % | $ 54.4 M | ||
|
EDAP TMS S.A.
EDAP
|
5.9 M | $ 4.1 | 2.76 % | $ 153 M | ||
|
Electromed
ELMD
|
39.3 M | $ 24.5 | 2.17 % | $ 207 M | ||
|
AdaptHealth Corp.
AHCO
|
382 M | $ 9.69 | 3.09 % | $ 1.31 B | ||
|
FONAR Corporation
FONR
|
23.5 M | $ 18.54 | 0.19 % | $ 122 M | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
CONMED Corporation
CNMD
|
132 M | $ 42.93 | -1.11 % | $ 1.33 B | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
AxoGen
AXGN
|
44.6 M | $ 29.44 | -1.31 % | $ 1.36 B | ||
|
Apyx Medical Corporation
APYX
|
22.2 M | $ 3.26 | 2.84 % | $ 113 M | ||
|
InMode Ltd.
INMD
|
8.41 M | $ 13.55 | -0.37 % | $ 876 M | ||
|
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | ||
|
IRadimed Corporation
IRMD
|
15.9 M | $ 105.35 | 1.02 % | $ 1.33 B | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Accuray Incorporated
ARAY
|
47.9 M | $ 0.52 | -0.36 % | $ 53.4 M | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
LivaNova PLC
LIVN
|
549 M | $ 66.26 | -3.17 % | $ 3.61 B | ||
|
Medigus Ltd.
MDGS
|
9.96 M | - | 10.28 % | $ 55.5 M | ||
|
Pulmonx Corporation
LUNG
|
102 M | $ 1.47 | -3.92 % | $ 57.5 M | ||
|
Cytosorbents Corporation
CTSO
|
35 M | $ 0.79 | -1.75 % | $ 43 M | ||
|
Medtronic PLC
MDT
|
10.8 B | $ 96.0 | -0.75 % | $ 123 B | ||
|
Align Technology
ALGN
|
1.76 B | $ 181.73 | -0.5 % | $ 13.6 B | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
Inari Medical
NARI
|
293 M | - | - | $ 4.23 B | ||
|
Butterfly Network
BFLY
|
39.8 M | $ 3.97 | 7.88 % | $ 840 M | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
Abbott Laboratories
ABT
|
12.3 B | $ 113.65 | 0.04 % | $ 198 B | ||
|
NuVasive
NUVA
|
634 M | - | - | $ 2.07 B | ||
|
Nevro Corp.
NVRO
|
310 M | - | - | $ 217 M | ||
|
BioSig Technologies
BSGM
|
11.6 M | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
6.89 B | $ 72.77 | -1.46 % | $ 108 B | ||
|
Orthofix Medical
OFIX
|
554 M | $ 12.98 | -0.42 % | $ 514 M |